Tools4Patient recently presented data showing its Placebell predicted placebo response in a Phase II randomized controlled trial (RCT) for osteoarthritis (OA). Placebell is technology using predictive modeling that is proven to reduce the impact of the placebo response in clinical trials under real-world conditions. Data from the Phase II RCT, “Predicting the Placebo Response in OA to Improve the Precision of the Treatment Effect Estimation,” was presented as a late-breaking abstract at the OARSI Connect Virtual World Congress on Osteoarthritis.
The placebo response is a major contributing factor to late-stage clinical trial failures in many therapeutic areas, and Placebell’s predictive method addresses this complex challenge. Placebell combines machine learning-based algorithms with individual patient psychology and personality data to predict the individual placebo response in a patient before the first dose of a drug is administered.
In the study, Tools4Patient applied a Placebell chronic pain model that had been built by meta-analysis that included individual data from 211 placebo-treated patients from several studies conducted by Tools4Patient. The model was pre-specified and used to predict placebo response in all trial patients receiving an intra-articular injection of a novel compound in the sponsored Phase II RCT. Results were compared for five different endpoints in the trial: average pain score, three components of the WOMAC battery focusing on pain, joint stiffness and physical function, and the patient global assessment score.
For more information, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.